Biolog Purchases Anaerobe Systems, Its Third Acquisition, Becoming the Knowledge Leader in Microbiology Research and Clinical Sample Prep

February 12, 2025 6:00 AM

Biolog, Inc., a leading provider of cell-based microbial and phenotypic profiling products and multiomic microbial identification services, today announced the acquisition of Anaerobe Systems, Inc. headquartered in Morgan Hill, California. The acquisition will be funded through a financing led by J.P. Morgan Life Sciences Private Capital with participation from existing investors BroadOak Capital Partners and Research Corporation...

Read more

Aspira Women's Health Announces Appointment of Ellen Beausang to the Board of Directors

February 11, 2025 8:30 AM

Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Ellen Beausang to the Board of Directors, effective February 10, 2025."We are pleased to welcome Ellen Beausang to the Board of Directors," said Michael Buhle, Chief Executive Officer of Aspira Women's Health. "Ellen brings an...

Read more

IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)

February 11, 2025 8:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the launch of Holiby™, a wellness brand offering scientifically formulated products for immune defense and sustained energy. This strategic expansion into the rapidly growing $75 billion wellness industry establishes a new revenue stream while IGC Pharma continues advancing its pharmaceutical pipeline focused on treatments for Alzheimer's disease and metabolic...

Read more

ZEO ScientifiX Provides Business Update to Stockholders and the Investment Community

February 11, 2025 7:00 AM

ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX), a clinical-stage biopharmaceutical company focused on the research and development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine and the development and sales of biologic products used in topical aesthetic applications, today provided a business update to stockholders and the investment community.The OpportunityAs of the end...

Read more

Next Gen Diagnostics Announces That the University of Pittsburgh Has Joined the NGD Consortium

February 10, 2025 12:00 PM

Next Gen Diagnostics (NGD), a pioneer in the development of machine learning models for whole genome sequence- (WGS-) based determination of bacterial antibiotic susceptibility, today announces that the University of Pittsburgh (Pitt) has joined the NGD Consortium, a part of NGD's effort (1) to develop a sequence-based diagnostic model to predict susceptibility to cefiderocol, an antibiotic developed by Shionogi & Co., Ltd....

Read more

Vicore to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

February 10, 2025 2:20 AM

Vicore Pharma Holding (STO:VICO)Stockholm, February 10, 2025 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that Ahmed Mousa, Chief Executive Officer, will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference.Presentation Date and Time: Wednesday, February 12, 2025, at 8:00 AM ET/2:00 PM CETPresenter: Ahmed Mousa,...

Read more

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

February 7, 2025 9:00 AM

enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that interim two-year follow-up data on 34 subjects from the VenoValve U.S. pivotal trial will be presented today by Dr. Matthew Smeds, Professor of Surgery in the Division of Vascular and Endovascular Surgery at Saint Louis University and Principal Investigator for the trial, at the...

Read more

Board Member of Biovica Resigns at Own Request

February 6, 2025 7:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica today announces that board member Ulf Jungnelius has resigned from the board at his own request, with immediate effect. Personal reasons are behind the decision."Due to my current situation, I am unable to fully participate in the board's work in the way I would like. Therefore, I have chosen to end my assignment," said Ulf Jungnelius."We have great respect for Ulf's decision...

Read more

Alligator Bioscience Successfully Completes End of Phase 2 Interaction with FDA For Mitazalimab

February 6, 2025 3:00 AM

Alligator Bioscience (STO:ATORX)FDA feedback validates the clinical development strategy and Phase 3 designFDA feedback confirms that the toxicology package is adequate for the BLA submissionRegulatory feedback significantly reduces program risk and Company remains on track for Phase 3 initiation during 2025Lund, Sweden - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the successful completion of its End of Phase 2 (EOP2)...

Read more

Nomination Committee for Biovica International AB for the 2025 Annual General Meeting

February 6, 2025 2:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) The Nomination Committee prior to the 2025 Annual General Meeting will consist of three members, who shall represent the two shareholders with the highest number of shares who accept the assignment to be part of the Nomination Committee as of December 31, 2024, and the Chairman of the Board. The Nomination Committee then appoints a chairman among its members.In accordance with the above...

Read more

Imagene Announces a Collaboration With Tempus to Advance AI-Driven Diagnostics for Non-Small Cell Lung Cancer

February 5, 2025 9:00 AM

Imagene, a leader in AI-powered Oncology Intelligence, today announced a collaboration with Tempus AI, Inc., a technology company leading the adoption of AI to advance precision medicine and patient care. The collaboration aims to advance cancer diagnostics by accelerating biomarker prediction, integrating AI-powered tools into clinical workflows, and enabling the commercialization of accessible diagnostic solutions.Imagene's innovative lung...

Read more

Adolore BioTherapeutics to Present CA8* Neuromodulating Gene Therapy at the 2025 NANS Annual Meeting

February 4, 2025 5:00 PM

Adolore BioTherapeutics ("Adolore" or the "Company"), is developing intracellularly-delivered neuromodulators that naturally reduce neuronal excitability to restore balance to the PNS/CNS to treat the underlying root cause of serious neurological disorders, including chronic pain, today announced that Roy C. Levitt, MD, the Company's founder, Chief Medical Officer, and Executive Chairman, Clinical Professor, University of Miami, and Principal...

Read more

Data4Cure Partners With Pfizer to Deliver New Insights With AI and Data-Driven Knowledge Graphs

February 4, 2025 3:00 PM

Data4Cure today announced an ongoing multi-year partnership with Pfizer, aimed at leveraging advanced analytics and knowledge graph AI to drive innovation in Pfizer's drug discovery and development programs.The collaboration and selected results from the partnership will be showcased at the upcoming Precision Medicine World Conference in Santa Clara, February 5-7, 2025.Using Data4Cure's Biomedical Intelligence® Cloud platform, Pfizer has been...

Read more

Mallia Therapeutics and Northway Biotech Announce Partnership for the Manufacturing of Soluble CD83 Protein for Hair Loss Treatment

February 4, 2025 5:00 AM

ERLANGEN, GERMANY AND VILNIUS, LITHUANIA / ACCESS Newswire / February 4, 2025 / Mallia Therapeutics ("Mallia"), a biopharmaceutical company developing novel treatments for hair loss, and Northway Biotech ("NBT"), a biologics Contract Development and Manufacturing Organization (CDMO), have announced a partnership for the development of the production process and manufacturing of Mallia's soluble CD83 protein (sCD83), a treatment aimed at...

Read more

Enalare Therapeutics Receives Second Component of a National Institutes of Health (NIH) Grant Award to Fund the Next Human Study of ENA-001

January 30, 2025 8:00 AM

Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life threatening critical care conditions and national health emergencies, announced today that it has been awarded the second component of a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH). Funding from the grant of approximately $2.5 million will be used to execute...

Read more

AmplifyBio Drives Key Conversations at Phacilitate's Advanced Therapy Week in Dallas

January 30, 2025 7:00 AM

AmplifyBio, a leading preclinical CRO and CDMO played a pivotal role in shaping discussions at Phacilitate's Advanced Therapy Week, held January 20-23 in Dallas, Texas. As usual, the event brought together global experts to discuss challenges and potential solutions to accelerate the commercialization of advanced therapies.J. Kelly Ganjei, CEO of AmplifyBio, moderated a session titled "The CAR-T Story and the Future of Cell Therapies." Joined by...

Read more

Adolore BioTherapeutics to Present CA8* Neuromodulating Gene Therapy at the 2025 NANS Annual Meeting

January 29, 2025 8:00 AM

Adolore BioTherapeutics ("Adolore" or the "Company"), is developing intracellularly-delivered neuromodulators that naturally reduce neuronal excitability to restore balance to the PNS/CNS to treat the underlying root cause of serious neurological disorders, including chronic pain, today announced that Roy C. Levitt, MD, the Company's founder, Chief Medical Officer, and Executive Chairman, Clinical Professor, University of Miami, and Principal...

Read more

Alligator Bioscience Announces Publication of Clinical Data for ATOR-1017 (evunzekibart) in the Journal for ImmunoTherapy of Cancer

January 29, 2025 4:00 AM

Alligator Bioscience (STO:ATORX)Publication validates encouraging clinical safety and tolerability in this first-in-human trialData show early signs of clinical efficacy in patients with advanced cancerPharmacokinetic and pharmacodynamic analyses demonstrate proof of mechanism for ATOR-1017Lund, Sweden - Alligator Bioscience (Nasdaq Stockholm:ATORX) today announces that clinical data for its 4-1BB agonist, ATOR-1017, has been published in the...

Read more

The Subscription Period in Alligator Bioscience's Rights Issue Begins Today

January 29, 2025 3:05 AM

Alligator Bioscience (STO:ATORX) Today is the first day of the subscription period in Alligator Bioscience AB's ("Alligator Bioscience" or the "Company") rights issue of units (the "Rights Issue"), which was resolved by the Board of Directors on 2 December 2024, and approved by the Extraordinary General Meeting held on 13 January 2025.Summary of the Rights IssueThe Rights Issue comprises a maximum of 2,810,919,873 units where each unit consists...

Read more

The FDA Grants Vicore’s Buloxibutid Fast Track Designation for Idiopathic Pulmonary Fibrosis

January 29, 2025 2:20 AM

Vicore Pharma Holding (STO:VICO)Stockholm, January 29, 2025 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to its lead candidate buloxibutid, recognizing its disease-modifying potential for the treatment of idiopathic pulmonary fibrosis...

Read more